The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
2d
French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...
are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...
A CD38 monoclonal antibody, Sarclisa binds to a specific epitope on the CD38 receptor on myeloma cells, ultimately inducing ...
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
IASO Bio’s FUCASO ® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with ...
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...
U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed ...
Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback